









Markets
/
Stocks
/
nasdaq-tenx
/

Tenax Therapeutics Inc

TENX

6.410USD

0.000

Close 09/19, 16:00（ET）Quotes delayed by 15 min

26.59MMarket Cap

LossP/E TTM



Tenax Therapeutics Inc

6.410

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

91 / 506

Overall Ranking

190 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

21.000

Target Price

+227.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 59.32.

Overvalued

The company’s latest PE is 2.18, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 2.98M shares, increasing 24.88% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 22.29K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.95, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.95

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 7.59, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 2.18, which is -100.07% below the recent high of -0.00 and 105.19% above the recent low of -0.11.

Score

Industry at a Glance

Previous score

7.59

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 91/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.20, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Tenax Therapeutics Inc is 20.00, with a high of 30.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

9.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

21.000

Target Price

+227.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Tenax Therapeutics Inc

TENX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 1.74, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 6.65 and the support level at 6.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.74

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.084

Buy

RSI(14)

70.950

Buy

STOCH(KDJ)(9,3,3)

78.522

Neutral

ATR(14)

0.173

High Vlolatility

CCI(14)

171.533

Buy

Williams %R

16.364

Overbought

TRIX(12,20)

0.165

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

6.292

Buy

MA10

6.187

Buy

MA20

6.076

Buy

MA50

6.041

Buy

MA100

5.935

Buy

MA200

6.046

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 71.83%, representing a quarter-over-quarter increase of 8.50%. The largest institutional shareholder is The Vanguard, holding a total of 22.29K shares, representing 0.49% of shares outstanding, with 25.28% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RTW Investments L.P.

378.35K

The Lind Partners, LLC

375.00K

+435.71%

Dellora Investments LP

351.07K

BVF Partners L.P.

339.55K

Millennium Management LLC

233.62K

+777.40%

Vivo Capital, LLC

208.33K

Morgan Stanley & Co. LLC

117.83K

+63.27%

Integral Health Asset Management, LLC

167.00K

Janus Henderson Investors

166.67K

Adar1 Capital Management LLC

68.74K

+98.14%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.91, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.